ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AVIR Atea Pharmaceuticals Inc

3.61
0.01 (0.28%)
After Hours
Last Updated: 18:00:02
Delayed by 15 minutes

Period:

Draw Mode:

Volume 167,612
Bid Price 3.55
Ask Price 3.72
News -
Day High 3.70

Low
2.765

52 Week Range

High
5.19

Day Low 3.585
Company Name Stock Ticker Symbol Market Type
Atea Pharmaceuticals Inc AVIR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.28% 3.61 18:00:02
Open Price Low Price High Price Close Price Prev Close
3.60 3.585 3.70 3.61 3.60
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,931 167,612 $ 3.64 $ 609,992 - 2.765 - 5.19
Last Trade Time Type Quantity Stock Price Currency
16:20:01 1 $ 3.61 USD

Atea Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
302.99M 84.16M - 0 -135.96M -1.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Atea Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AVIR Message Board. Create One! See More Posts on AVIR Message Board See More Message Board Posts

Historical AVIR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.054.13993.563.71430,280-0.44-10.86%
1 Month3.684.13993.563.79255,288-0.07-1.90%
3 Months4.374.603.563.95314,143-0.76-17.39%
6 Months3.004.602.7653.69396,5440.6120.33%
1 Year4.695.192.7653.75453,347-1.08-23.03%
3 Years23.5846.90992.76513.211,036,284-19.97-84.69%
5 Years29.9494.17372.76515.50955,862-26.33-87.94%

Atea Pharmaceuticals Description

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

Your Recent History

Delayed Upgrade Clock